Loading
CD30 is the antigen of Hodgkin Reed-Sternberg cells and anaplastic large cell lymphoma. Brentuximab vedotin is labelled for Hodgkin lymphoma without a CD30 test and for peripheral T-cell lymphomas that express it.
CD30 is read by immunohistochemistry; classical Hodgkin lymphoma and ALCL are uniformly positive, other T-cell lymphomas variably so. Brentuximab vedotin (Adcetris) is a CD30-directed antibody-drug conjugate labelled for classical Hodgkin lymphoma (first-line with chemotherapy, consolidation, relapsed), systemic ALCL and CD30-expressing peripheral T-cell lymphomas (ECHELON-2 required at least 10 percent of cells positive) and CD30-expressing mycosis fungoides or primary cutaneous ALCL. No numeric threshold appears in the indications.
In plain words · CD30 is a protein on the malignant Reed-Sternberg cells of Hodgkin lymphoma and on some T-cell lymphomas, and the address for the ADC brentuximab vedotin.
In Hodgkin lymphoma CD30 is taken as read and brentuximab vedotin is an option without further testing. In a T-cell lymphoma the pathologist reports whether the cells express CD30; if they do, brentuximab vedotin with chemotherapy is on label as first treatment.
Written only from the label or guideline text cited on this page. Not medical advice; your own report and the reading your team gives it come first.
CD30 detected on tumour cells by immunohistochemistry; the Hodgkin indications assume it, the T-cell lymphoma indications say CD30-expressing without a percentage (ECHELON-2 used 10 percent or more).
“ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of: • Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine”
ADCETRIS prescribing information| Threshold | Drug | Cancer | Regulator | Source |
|---|---|---|---|---|
| CD30-expressing (no percentage in the label; ECHELON-2 used >= 10%) Adcetris indication for previously untreated systemic ALCL or other CD30-expressing peripheral T-cell lymphomas in combination with cyclophosphamide, doxorubicin and prednisone. | Brentuximab vedotin | Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) | FDA | label |
Matched on the name and aliases of the readout in the title, setting and summary of each trial; a match is a mention, not proof the readout was an entry criterion.
Shares CD19 expression (CD19-positive), What it costs to aim at a lineage antigen, Immunohistochemistry (IHC), Non-Hodgkin lymphoma (all types) and the tags biomarker, surface-antigen.
Shares CD19 expression (CD19-positive), Non-Hodgkin lymphoma (all types) and the tags biomarker, surface-antigen.
Shares Immunohistochemistry (IHC) and the tags biomarker, surface-antigen.
Shares Immunohistochemistry (IHC) and the tags biomarker, surface-antigen.
Shares the tags biomarker, surface-antigen.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Non-Hodgkin lymphoma (all types) and the tags biomarker, surface-antigen.
Shares Immunohistochemistry (IHC) and the tags biomarker, surface-antigen.
Shares Immunohistochemistry (IHC) and the tags biomarker, surface-antigen.